Christine Yee with Darpan Bohara and Yashna Sureka of Smith College in the U.S. will develop a fingerprint scanner that can link to phone networks and banks to enable merchants to easily and quickly accept mobile money payments in India. Fingerprint identification is relatively secure and will simplify the payment process so people with different levels of literacy can use it. They will test their prototype by giving deposits to a group of students and scanners to local merchants in Nelamangala, India, and providing the associated knowledge and resources needed to use their mobile money transfer system.

Samuel Alcaine of the University of Massachusetts Amherst in the U.S. will engineer bacteriophage (viruses that infect bacteria) to produce an antimicrobial compound that helps avoid bacteria such as enteroaggregative Escherichia coli developing resistance to the phage, thereby increasing their value for treating associated childhood diseases. Phage could be valuable for treating intestinal diseases that cause severe morbidity and mortality in developing countries as they can selectively destroy pathogenic bacteria. However, some bacteria rapidly develop resistance to the phage, which renders them useless. By inducing phage-infected bacteria to also release a toxic substance (bacteriocin), this would destroy any potentially resistant neighboring bacteria. They will engineer T7 bacteriophage to express one of two selected bacteriocins and test their ability to circumvent phage resistance in E. coli.

The project aims to ensure food-security throughout the entire year in a rural district by storing food through an innovative technology known as the Solar Conduction Dryer. It also aims to add extra income to women farmers from the sale of the dehydrated products of this technology, while providing valuable lessons in post-harvest losses.

Simon Foote of the Menzies Research Institute at the University of Tasmania in Australia will use "forward genetic screening" approaches identify mutations that confer resistance after exposure to malaria parasites. The team will use this powerful information to develop drug therapies that target the human host and mimic these protective genetic effects.

Mauricio Lima Barreto from Fiocruz in Brazil will evaluate the impact of social and economic inequalities, and the national family allowance program (Bolsa Familia), on healthy births and early childhood health and development. They will setup a cohort, which will be derived from a central database of named households created to support Brazil’s social programs, and a data center for the analysis. They will use a variety of demographic, economic and social data on families, as well as information on births and childhood deaths, and child growth. The impact of receiving family allowance, and the effect of its value and duration, on outcomes such as birth weight, prematurity, fetal death, and early childhood growth will also be measured. This approach will generate evidence to help maximize the value of the social program and inform future related policies.

Edward Dolk of Utrecht University in the Netherlands proposes using two-sided antibodies, which bind to HIV and to transport receptors in the epithelium. Binding these receptors will cause excretion of the HIV particles outside of the body, thereby reducing viral load.

Because human carriage of pneumococcus usually results in improved immunity to future infections without any development of disease, Stephen Gordon of the Liverpool School of Tropical Medicine in the United Kingdom will use an intranasal inoculation with a safe strain of the bacteria to study the mechanisms of mucosal immunity in the lungs and to explore the potential for a vaccine based on his findings. In this project's Phase I research, Gordon successfully demonstrated that human carriage of pneumococcus provides improved immunity to future infections, and that nasal inoculation immunizes the lungs against the pathogen. In Phase II, Gordon will work to assess the reproducibility of his model to ensure its robustness as a candidate for a pneumococcal vaccine.

Peter Lubega Yiga of AdhocWorks Foundation in South Africa will test the efficacy of small household containers in which a non-toxic formulation is mixed with water, releasing carbon dioxide and alcohol vapors as a way to repel mosquitos. The investigators will test the device in independent field trials to optimize its usefulness as an alternative to insecticides.

Ruth Foster of TIWA, LLC in the U.S. will develop a finance application tool using money pictures to enable illiterate users to make accurate transactions. They will design and test a tablet with touch screen and build associated software for consumers that can be used to scan barcodes, or manually add products and prices. The final cost of the purchases will be automatically displayed using images of real money, which the consumer can then use to pay the correct amount.

Noel Elman of GearJump Technologies in the U.S. will produce a biodegradable device that can be used outdoors for the controlled release of pesticides and mosquito repellants in a defined area. Current methods for reducing malaria transmission by chemically targeting mosquitoes are quite crude and can cause widespread or prolonged exposure of the human population to toxic chemicals. They will build a functional microdispenser (FMD) from biodegradable polymer that releases chemicals contained in a porous membrane upon exposure to oxygen, which can be controlled by various parameters such as pore size. These FMDs can be manufactured at low cost using 3D printers, and will be tested in large outdoor cages.

Chen Yangchao of the Chinese University of Hong Kong proposes developing a lentiviral vector that targets the entry and replication of influenza viruses in domestic chickens. The team plans to test the ability of these modified chickens to be resistant to various influenza viruses in an effort to reduce the frequency of flu epidemics in poultry and, ultimately, in humans.

Paul Kim of Johns Hopkins University in the U.S. will modify HIV by removing the viral genome and replacing the outer domain of the gp120 protein, used by the virus to invade host immune cells, with receptors normally used by gp120 to bind to host cells. When this modified ghost virus encounters native HIV during an infection, hidden epitopes are exposed to the host immune system, stimulating antibodies to clear the infection.